[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353594-105":59,"doc-detail-353594-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","improving-aerobic-capacity-in-patients-with-advanced-non-small-cell-lung-cancer-study-protocol-of-the-3-armed-randomized-controlled-breath-trial","Improving aerobic capacity in patients with advanced non-small cell lung cancer - study protocol of the 3-armed randomized controlled BREATH trial","","The BREATH study protocol evaluates exercise therapy for patients with advanced non-small cell lung cancer (NSCLC, stage IIIB–IV) receiving first- or second-line systemic therapy in palliative care. Background addresses high symptom burden—fatigue, pain, dyspnea, weight loss—alongside cardiovascular and pulmonary comorbidities and limited guideline prioritization. A prospective three-arm randomized controlled trial (n=104) compares exercise recommendations, endurance plus breathing, and combined endurance plus resistance over 12 weeks, assessing aerobic capacity (VO2 peak) and multiple patient-centered outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/improving-aerobic-capacity-in-patients-with-advanced-non-small-cell-lung-cancer-study-protocol-of-the-3-armed-randomized-controlled-breath-trial/353594/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/improving-aerobic-capacity-in-patients-with-advanced-non-small-cell-lung-cancer-study-protocol-of-the-3-armed-randomized-controlled-breath-trial/353594.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the primary outcome of the BREATH trial?","Question",{"text":113,"@type":114},"The primary outcome is improvement of aerobic capacity, measured by VO2 peak.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many participants are enrolled and how are they assigned to study arms?",{"text":118,"@type":114},"A total of 104 patients are randomized in a 2:1:1 ratio into control (exercise recommendations) or two intervention arms: endurance plus breathing, or combined endurance and resistance.",{"name":120,"@type":111,"acceptedAnswer":121},"What interventions and follow-up time points are included?",{"text":122,"@type":114},"Intervention groups exercise twice weekly for 12 weeks, with outcomes assessed at baseline, 12 weeks, and 24 weeks.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},353594,1790387062,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","De Lazzari et al. Trials (2026) 27:88  \n[https://doi.org/10.1186/s13063-025-09416-2](https://doi.org/10.1186/s13063-025-09416-2)  \nTrials  \n STUDY PROTOCOL Open Access  \nImproving aerobic capacity in patients  \nwith advanced non-small cell lung cancer: study protocol of the 3-armed randomized controlled BREATH trial  \nNico De Lazzari1* , Marcel Wiesweg3, Miriam Götte2 , Jan Franco 1 , Raluca Ileana Mincu6,  \nJohannes Jäger7 , Eva‑Maria Huessler4,5 , Nils Kuklik4,5, Andreas Stang4, Matthias Totzeck6 and MitraTewes1  \nAbstract  \nBackground Lung cancer is one of the most common cancers in Germany, with around 56,000 new cases diagnosed in 2020. Approximately 65% are diagnosed at advanced stages, where symptoms such as fatigue, pain, dyspnea, and weight loss are prevalent. These patients often suffer from cardiovascular and pulmonary comorbidities, which interact with treatment toxicity, outcome, and increase treatment costs. Although exercise therapy is proven to alle‑ viate cancer‑related symptoms and to improve quality of life, current lung cancer treatment guidelines fail to ade‑ quately prioritize its crucial role.  \nMethods The Better symptom contRol with Exercise in pAtients wiTH advanced non‑small cell lung cancer (BREATH) study is a prospective, three‑arm randomized controlled trial (RCT) designed to assess the impact of exercise therapy on patients with advanced NSCLC (stage IIIB‑IV) who are receiving first‑ or second‑line systemic therapy in the pallia‑ tive setting. Patients (n= 104) are randomized in a 2:1:1 ratio into a control group (receiving exercise recommenda‑ tions) or one of two intervention arms: endurance training and breathing exercise or combined endurance and resist‑ ance training. The intervention groups will exercise twice a week for 12 weeks. The control group participants will be randomized again in a 1:1 ratio into one of the two intervention arms after completion of the control period. The study will assess outcomes at baseline, 12 weeks, and 24 weeks. The primary outcome is improvement of aerobic capacity (VO2 peak). Secondary outcomes include quality of life, fatigue, adherence to exercise, and adverse events. Patient representatives were involved in all stages of protocol development.  \nDiscussion The BREATH study addresses a significant gap in the current management of advanced lung cancer treat‑ ment by evaluating the impact of different exercise treatment protocols to reduce symptoms and improve clinical outcome. The study design and exercise program aim to enhance adherence and optimize patient‑related outcomes. The results of the BREATH study have the potential to influence future guidelines and improve the management of patients with advanced NSCLC.  \nTrial registration [ClinicalTrials.gov](ClinicalTrials.gov) NCT06374160 . Registered on April 18, 2024.  \nProtocol version 1. 3, dated 18 November 2025.  \n*Correspondence: Nico De Lazzari  \nnico. delazzari@uk‑[essen.de](essen.de)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses","cbCailFOmn4SYTvx","https://ap.wps.com/l/cbCailFOmn4SYTvx","pdf",1225256,13,"English","# Abstract\n## Background\n## Methods\n## Discussion\n# Keywords\n## Background","[{\"question\":\"What is the primary outcome of the BREATH trial?\",\"answer\":\"The primary outcome is improvement of aerobic capacity, measured by VO2 peak.\"},{\"question\":\"How many participants are enrolled and how are they assigned to study arms?\",\"answer\":\"A total of 104 patients are randomized in a 2:1:1 ratio into control (exercise recommendations) or two intervention arms: endurance plus breathing, or combined endurance and resistance.\"},{\"question\":\"What interventions and follow-up time points are included?\",\"answer\":\"Intervention groups exercise twice weekly for 12 weeks, with outcomes assessed at baseline, 12 weeks, and 24 weeks.\"}]","Improving aerobic capacity in patients with advanced non-small cell lung cancer - study protocol of the 3-armed randomized controlled BREATH trial | PDF",1790106224,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09ce6d788e2eb28b9e64c9ce5978ade9.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a2546f966982fc2e23bbdcac42167f4.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc62703a1783cb9148427ab57a60ed74.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/629c3aac60f4306981e93800768ca956.webp",980,1301]